Erlotinib相关论文
Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin h
...
目的 探讨CD146对获得性Erlotinib耐药肺腺癌细胞上皮-间充质转化(EMT)的作用及机制.方法 采用不同浓度的Erlotinib作用于肺腺癌细......
Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinica
...
目的探讨放射治疗联合厄洛替尼治疗老年局部晚期非小细胞肺癌(NSCLC)的有效性和安全性。方法选取2015年8月至2016年2月运城市中心......
目的观察厄洛替尼联合卡培他滨方案一线治疗局部晚期或伴转移的胰腺癌的疗效和安全性。方法将40例未接受过全身化疗的局部晚期或伴......
目的观察分析厄洛替尼联合调强放疗治疗局部进展期胰腺癌的疗效和安全性。方法回顾性分析23例局部进展期胰腺癌患者的临床资料，治疗......
目的探讨厄洛替尼在脂多糖（lipopolysaccharide，LPS）诱导的小鼠急性肺损伤（acute lung injury，ALI）中的作用及对肺表面活性物质相关蛋白A......
目的观察葡萄糖调节蛋白78(glucose-regulated protein 78,GRP78)对EGFR L858R突变的非小细胞肺癌对erlotinib敏感性的影响,为最终......
目的比较表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)与化疗二线治疗晚期非小细胞肺癌的有效性和安全性。方法检索Cochrane Libr......
Efficacy and clinical/molecular predictors of erlotinib monotherapy for Chinese advanced non-small c
Background A retrospective analysis of clinical data were conducted reviewing patients who were given erlotinib at Pekin......
Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure
Background Several clinical trials showed that erlotinib was effective after the failure of gefitinib in advanced non-sm......
Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinica
Background Serum expression of cytokines may provide information about the clinical outcome of advanced non-small cell l......
Initial Progression-Free Survival affer Non-First Line TKIs Therapy Potentially Guides Immediate Tre
Objective The standard therapy aft er failure of the initial non-fi rst line epidermal growth factor receptor tyrosine k......
Effect of application of markers and immune function of patients with tumor of erlotinib combined wi
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
目的探讨厄洛替尼2线或3线治疗化疗失败晚期非小细胞肺癌（NSCLC）的疗效及不良反应。方法收集2008年3月至2010年6月化疗失败的ⅢB／Ⅳ期......
目的 探讨厄洛替尼对ⅢA期非小细胞肺癌(NSCLC)患者手术切除率和肺癌根治率及术后并发症的影响.方法 31例ⅢA期肺癌患者入A组(厄洛......
Initial Progression-Free Survival affer Non-First Line TKIs Therapy Potentially Guides Immediate Tre
Objective The standard therapy aft er failure of the initial non-fi rst line epidermal growth factor receptor tyrosine k......
厄洛替尼是一种高效、高特异性、可逆的表皮生长因子受体酪氨酸激酶抑制剂(EGFRTKI),通过抑制EGFR(HER1)的自身磷酸化,从而抑制下......
Sur vival Model Established by Combined Serum Tumor Markers in Predicating the Effect of Erlotinib o
Objective: To investigate the relationship of serum pulmonary surfactant-associated pretein (SP-D), transforming growth ......
表皮生长因子受体(EGFR)异常表达与肿瘤细胞的增殖、血管生成、肿瘤侵袭、转移及细胞凋亡的抑制有关.EGFR小分子抑制剂埃罗替尼(er......
目的:探讨全脑放射治疗后服用厄洛替尼引起的头部皮肤放射治疗回忆反应。方法:对右肺腺癌(T3N2M1)骨转移患者行全脑放疗,DT:40 Gy,......
目的 观察厄洛替尼治疗中国晚期非小细胞肺癌(NSCLC)患者的疗效和安全性.方法 2005年11月至2009年3月,用厄洛替尼150 mg/d治疗519......
目的 观察厄洛替尼单药治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应.方法 104例晚期NSCLC患者给予厄洛替尼150 mg口服治疗,每日1......
目的:探讨新型靶向治疗药物厄洛替尼对人卵巢癌细胞株SKOV3的作用。方法:体外培养人卵巢癌细胞株SKOV-3,采用MTT(噻唑蓝)检测不同......
目的探讨体外转染靶向生存素的小干扰RNA(siRNA)是否能够增强厄洛替尼对肺腺癌细胞的增殖抑制、凋亡诱导作用,以及厄洛替尼是否能......
Colorectal cancer constitutes one of the most common malignancies and the second leading cause of death from cancer in t......
目的研究厄洛替尼对非小细胞肺癌(NSCLC)脑转移细胞PC14/B侵袭转移能力的抑制作用。方法 PC14/B细胞随机分为对照组及3个浓度实验......
Efficacy and clinical/molecular predictors of erlotinib monotherapy for Chinese advanced non-small c
Background A retrospective analysis of clinical data were conducted reviewing patients who were given erlotinib at Pekin......
Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure
Background Several clinical trials showed that erlotinib was effective after the failure of gefitinib in advanced non-sm......
The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non
...
AIM: To investigate the effect and mechanism of action of erlotinib,an epidermal growth factor receptor (EGFR) small mol......
